Mumbai, Nov. 18 -- Piramal Pharma, acting under the authority delegated by the Board, has approved the exercise of the Company's call option to acquire the balance 26% equity stake in Yapan Bio (Yapan), a subsidiary of the Company, from its existing shareholders (the Proposed Transaction).

Published by HT Digital Content Services with permission from Capital Market....